Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2023-10 · 23 (10) · 719-732
DOI: 10.1016/j.clml.2023.05.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-10. Verfasst von Sergio Giralt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic ad…. Hauptthemen laut MEDLINE: Multiple Myeloma, Agammaglobulinemia, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSL Behring.
Abstract (Originalsprache)
Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor antibody function. SAD is common in patients with multiple myeloma (MM) due to underlying disease pathophysiology and treatment-related immune system effects. Patients with SAD are more susceptible to infections and infection-related morbidity and mortality. With therapeutic advancements improving MM disease control and survival, it is increasingly important to recognize and treat the often-overlooked concurrent immunodeficiency present in patients with MM. The aims of this review are to define SAD and its consequences in MM, increase SAD awareness, and provide recommendations for SAD management. Based on expert panel discussions at a standalone meeting and supportive literature, several recommendations were made. Firstly, all patients with MM should be suspected to have SAD regardless of serum antibody concentrations. Patients should be evaluated for immunodeficiency at MM diagnosis and stratified into management categories based on their individualized risk of SAD and infection. Infection-prevention strategy education, early infection reporting, and anti-infective prophylaxis are key. We recommend prophylactic antibiotics or immunoglobulin replacement therapy (IgRT) should be considered in patients with severe hypogammaglobulinemia associated with a recurrent or persistent infection. To ensure an individualized and efficient treatment approach is utilized, patient's immunoglobin G concentration and infection burden should be closely monitored throughout treatment. Patient choice regarding route and IgRT treatment is also key in reducing treatment burden. Together, these recommendations and proposed management algorithms can be used to aid physician decision-making to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic address: GiraltS@mskcc.org.
- Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom.
- Department of Hematology, Ghent University Hospital, Ghent, Belgium.
- Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH, United States.
- Rochester Regional Health, Rochester, NY, United States; University of Rochester School of Medicine & Dentistry, Rochester, NY, United States.
- Department of Medicine, Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Förderung
- CSL Behring
Zitieren
APA
Giralt, S., Jolles, S., Kerre, T., Lazarus, H. M., Mustafa, S. S., Papanicolaou, G. A., Ria, R., Vinh, D. C., & Wingard, J. R. (2023). Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 23(10), 719-732. https://doi.org/10.1016/j.clml.2023.05.008
Vancouver
Giralt S, Jolles S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, et al. Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2023;23(10):719-732. doi:10.1016/j.clml.2023.05.008
BibTeX
@article{Giralt2023,
author = {Giralt, Sergio and Jolles, Stephen and Kerre, Tessa and Lazarus, Hillard M and Mustafa, S Shahzad and Papanicolaou, Genovefa A and Ria, Roberto and Vinh, Donald C and Wingard, John R},
title = {Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
volume = {23},
number = {10},
pages = {719--732},
doi = {10.1016/j.clml.2023.05.008}
}
EUVIMED